 OptiNoses Xhance is already approved in one indication with another set to read out pivotal data from two trials in late 2021 and early 2022. Xhance had 48.4 million in sales in the sinusitis patients with nasal polyps in 2020 and looks to grow that to at least 80 million in 2021. 